Innoviva Inc (INVA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Innoviva Inc   (NASDAQ: INVA)


Innoviva Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Innoviva Inc's ROI in the second quarter of 2026?
Innoviva Inc achieved a return on average invested assets (ROI) of 23.33 % in its second quarter of 2026, this is above INVA's average return on investment of 17.26%.
Innoviva Inc invested over the 12 months ending in its second quarter of 2026 $1,531 million

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 42 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 61 to 133.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 56.17 % 37.14 % 14.17 % -0.3 % -12.03 %
Y / Y Net Income Change TTM 824.31 % - - - -
Investment (TTM) in Millions 1,656 1,658 1,488 1,323 1,027
Return On Investment (TTM) 23.33 % 36.71 % 22.62 % 11.82 % 3.94 %
INVA's Overall Ranking # 133 # 61 # 172 # 429 # 1310
Seq. Investment Change TTM 11.44 % 14.61 % 11.3 % 9.86 % -2.14 %
Seq. Net Income Change TTM -29.17 % 85.99 % 112.94 % 229.49 % -
Net Income (TTM) in Millions 357 504 271 127 39

INVA Company Profile >> Back to INVA Roi Comparisons >> See Annual INVA Return On Investment



Return On Investment INVA's Ranking
Within: No.
Industry # 22
Sector # 43
Overall # 133

Return On Investment Statistics
High Average Low
113.51 %
17.26 %
-34.45 %
(Dec 31 2018)   (Mar 31 2013)







Financial Statements
Innoviva Inc's II. Quarter Investments $ 1,656 Millions INVA's Balance sheet
Innoviva Inc's II. Quarter Income $ -83 Millions Quarterly INVA's Income Statement
INVA's Income by Division See INVA's Income by Division


INVA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,488 1,001 1,122 1,010 1,032
Y / Y Investment Growth 48.65 % -10.79 % 11.07 % -2.11 % -2.79 %
Net Income in Millions 271 23 180 220 369
Y / Y Net Income Growth 1059.22 % -86.98 % -18.41 % -40.28 % 25.53 %
Annual Return On Investment 18.23 % 2.34 % 16.02 % 21.81 % 35.75 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 18.23 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
INVA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for INVA's Competitors
Subscribers only: Roi for Innoviva Inc's Suppliers
Subscribers only: Return On Investment for INVA's Customers

Other Ratios
INVA's Roa INVA's Inventory Turnover Ratio INVA's Growth Rates INVA's Dividend Statistics
INVA's Profitability Ratios INVA's Asset Turnover Ratio INVA's Dividend Growth
INVA's Roe INVA's Valuation Ratios INVA's Financial Strength Ratios INVA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %

Date modified: 2026-09-11T18:47:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.